aap Implantate AG: 30% sales growth in trauma in the first quarter of 2017
aap Implantate AG ("aap") made a successful start in financial year 2017 as a pure player in trauma with significant sales growth. According to preliminary figures, trauma sales rose in the first three months of the current year compared to the corresponding period in the last year by 30% to EUR 2.9 million (Q1/2016: EUR 2.2 million). Overall, aap increased total sales in the first quarter of 2017 in comparison to the first three months of last year by 23% to EUR 3.1 million (Q1/2016: EUR 2.5 million). Thereby the company realized a value slightly above the guidance provided in February of EUR 1.8 million to EUR 2.8 million.
In EUR million Q1/2017 Q1/2016 Change on year Traumathereof North America and Europe thereof RoW 2.92.1 0.8 2.21.8 0.4 +30%+16% +87% Other (mainly discontinued activities) 0.2 0.3 -33% Sales 3.1 2.5 +23%
Overall, it turns out that the dynamic development in North America and Europe continued in the first quarter of 2017. This reflects simultaneously the progress in the aimed distribution focus on established markets such as North America, the DACH region and further European countries. Besides this the sales development in BRICS and SMIT states shows a positive trend towards stabilization.
The preliminary results contained in this press release are based on management's initial analysis of operations for the period ended on 31 March 2017, and are therefore subject to change. aap plans to publish its final results for the first quarter of 2017 on 15 May 2017.
_______________________________________________________________________________________aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -About aap Implantate AGaap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.Forward-looking statement This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments. For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: email@example.com
24.04.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English
Company: aap Implantate AG Lorenzweg 5 12099 Berlin
Germany Phone: +49 (0) 30 75 01 90 Fax: +49 (0) 30 75 01 91 11 E-mail: firstname.lastname@example.org Internet: www.aap.de ISIN: DE0005066609 WKN: 506660 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service